Prostate-Specific Membrane Antigen-Targeted Imaging With [18F]DCFPyL in High-Grade Gliomas

Roberto Andres Salas Fragomeni, Joshua R. Menke, Matthias Holdhoff, Clare Ferrigno, John Joseph Laterra, Lilja B. Solnes, Mehrbod S. Javadi, Zsolt Szabo, Martin G. Pomper, Steven P. Rowe

Research output: Contribution to journalArticlepeer-review

Abstract

High-grade gliomas (World Health Organization grade III-IV) are highly lethal primary brain tumors. Imaging modalities, including MRI and FDG PET, provide a limited ability to differentiate treatment effects (such as radiation necrosis) from recurrent or residual tumor. As the first step in validating the applicability of prostate-specific membrane antigen (PSMA)-targeted imaging in high-grade gliomas, we evaluated the ability of the PSMA-targeted small molecule [F]DCFPyL (2-(3-(1carboxy-5-(6-[F]fluoro-pyridine-3-carbonyl)-amino]-pentyl)-ureido)-pentanedioic acid) to image high-grade gliomas in a series of 3 prospectively recruited patients. We found [F]DCFPyL binds PSMA in the neovasculature of glioblastoma multiforme and tumor cells of anaplastic astrocytoma.

Original languageEnglish (US)
Pages (from-to)e433-e435
JournalClinical nuclear medicine
Volume42
Issue number10
DOIs
StatePublished - Oct 1 2017

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging

Fingerprint Dive into the research topics of 'Prostate-Specific Membrane Antigen-Targeted Imaging With [18F]DCFPyL in High-Grade Gliomas'. Together they form a unique fingerprint.

Cite this